BackCoherus Biosciences Overview

Coherus Biosciences Receivables

Coherus Biosciences's receivables is $14M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$14.25M
178.98% YoYΔ $9.14M vs prior year quarter

Peer trimmed avg / median

Loading

Coherus Biosciences Receivables History

Loading

Coherus Biosciences vs. peers: Receivables Comparison

Loading

Coherus Biosciences Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Coherus Biosciences (CHRS) FAQ

As of the most recent data (June 2026), CHRS shows a receivables of $14M. That compares with $5.1M in the prior-year period — up 179.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CHRS's receivables is now $14M (was $5.1M) — a 179.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Coherus Biosciences is outperforming or lagging.

Tracking CHRS's receivables over time shows whether Coherus Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $14M That compares with $5.1M in the prior-year period — up 179.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Coherus Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $14M) with ownership activity and broader fundamentals.

Coherus Biosciences's receivables is $14M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.